Oral immunoadjuvant activity of lipophilic derivatives of N-acetylglucosaminyl-beta(1-->4)-N-acetylmuramyl-L-alanyl-D-isoglutamin yl-(L)- 2,6-meso-diaminopimeric acid-(D)-amide.
Twenty-four kinds of the acylated, amidated or esterified derivatives of N-acetylglucosaminyl (GlcNAc)-beta(1-->4)-N-acetylmuramyl (MurNAc)-L-alanyl (Ala)-D-isoglutaminyl (isoGln)-(L)-meso-2,6-diaminopimeric acid (A2pm)-(D)-amide (GMP3-A) which were prepared by chemical modifications of an enzymatic hydrolysate of Lactobacillus plantarum cell-wall peptidoglycans were examined for oral adjuvant activity by gastric intubation with bovine serum albumin (BSA) in liposomes into BALB/c mice. The gastric intubation of GlcNAc-beta(1-->4)-MurNAc-L-Ala-D-isoGln-(L)- stearoyl-(D)-meso-A2pm-(D)-amide-(L)-O-octyl, -nonyl and -dodecyl esters exhibited the most marked oral adjuvant activity in terms of enhanced production of serum anti-BSA IgG antibody. Some derivatives showed a less marked adjuvanticity and others were totally inactive. Thus the oral adjuvanticity of test lipophilic derivatives of GMP3-A in liposomes was dependent upon their chemical structure.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000032:analysis*; D000284:Administration, Oral; D000818:Animals; D002240:Carbohydrate Sequence; D007778:Lactobacillus / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D010457:Peptidoglycan; D011104:Polyisoprenyl Phosphate Oligosaccharides / Q000008:administration & dosage / Q000276:immunology*
D000276:Adjuvants, Immunologic; D010457:Peptidoglycan; D011104:Polyisoprenyl Phosphate Oligosaccharides; C074776:N-acetylglucosaminyl-N-acetylmuramyl(tripeptide)-pyrophosphate-undecaprenol